Telitacicept in the Treatment of Pediatric IgA Vasculitis-Associated Nephritis

Starting soon

Conditions studied: IgAVN, IgA Vasculitis

In brief

To further evaluate the efficacy and safety of Telitacicept in the treatment of pediatric IgA vasculitis nephritis (IgAVN) within real-world settings, this study employs a multicenter, retrospective and prospective observational research design. It aims to compare the efficacy of Telitacicept with that of glucocorticoids, thereby providing clinicians with a reference for the rational and standardized application of Telitacicept.

Key facts

Study ID

NCT07354503

Run by

The Children's Hospital of Zhejiang University School of Medicine

People needed

300

Starts

2026-01-01

Expected to finish

2028-06-30

Last updated by the study team

2026-01-21

Who can join

Age: 3 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 3-17 years;
• Patients diagnosed with IgA vasculitis nephritis (IgAVN) based on clinical manifestations and renal pathological diagnosis;
• Urinary protein quantification requirements: urinary protein/creatinine ratio (UPCR) of ≥1 mg/mg (100 mg/mmol);
• Estimated glomerular filtration rate (eGFR) calculated using the modified Schwartz formula of ≥60 mL/min/1.73 m².
• Renal biopsy is optional (if a renal biopsy is performed, cases classified as International Society of Nephropathology (ISKDC) grade ≥IV must be excluded).

You may not qualify if…

• Patients with congenital or acquired immunodeficiency, or those with concurrent tuberculosis, active cytomegalovirus (CMV), Epstein-Barr virus(EBV), hepatitis B, hepatitis C, Human Immunodeficiency Virus(HIV) infection, deep fungal infections, or other active infections;
• Patients exhibiting the following abnormal laboratory indicators at the time of initial diagnosis: moderate to severe neutropenia (≤1000/μL); moderate to severe anemia (hemoglobin <9.0 g/dL); thrombocytopenia (platelet count <100×10\^12/L); or abnormal liver function (Alanine Aminotransferase(ALT), Aspartate Aminotransferase(AST), or bilirubin exceeding 2.5 times the upper limit of normal and persistently elevated for 2 weeks);
• Patients with a history of tumors or severe cardiovascular, digestive system, hematological, endocrine, or other systemic diseases;
• Patients with concurrent other urinary system diseases (such as hereditary kidney diseases, etc.);
• Subjects with severe osteoporosis requiring treatment;
• Subjects diagnosed with uncontrolled mental illness or intellectual disabilities;
• Subjects who have received B-cell targeted therapy within the last 6 months;
• History of major organ transplant or hematopoietic stem cell/cell/bone marrow or kidney transplant;
• Vaccination with live attenuated vaccines within 1 month prior to treatment;
• Use of various traditional Chinese medicines for treating kidney diseases during the treatment period (patients who have previously used traditional Chinese medicine can be included, but are strictly prohibited from using it after receiving treatment according to the protocol);
• Incomplete clinical data.

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.